Back to Search
Start Over
Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
- Source :
-
Acta dermato-venereologica [Acta Derm Venereol] 2018 Apr 16; Vol. 98 (4), pp. 406-410. - Publication Year :
- 2018
-
Abstract
- Nivolumab response rate is 40% in metastatic melanoma. Few studies have evaluated pre-treatment biomarkers predictive of response. The aim of this study was to identify potential peripheral blood biomarkers associated with survival in patients with advanced melanoma treated with nivolumab. All advanced melanoma cases treated with anti-programmed cell death protein 1 (anti-PD1) over a 3-year period in the Dermato-Oncology Department, Nantes, France were identified. For each case, 9 potential blood biomarkers were identified. Bivariate and multivariate analyses, adjusted for the American Joint Committee on Cancer (AJCC) classification stage, Eastern Cooperative Oncology Group (ECOG) performance status, lactate dehydrogenase (LDH) level and failure to respond to first-line therapy, were used to test the association between biomarkers and overall survival (primary outcome) or progression-free survival (secondary outcome). Increased monocyte count, leukocyte/lymphocyte ratio and neutrophil/lymphocyte ratio were significantly associated with decreased overall survival after bivariate and multivariate analyses. Increased monocyte count was also significantly associated with decreased progression-free survival. These blood variables are easily measured and could help to predict patient response before the introduction of anti-PD1 therapy.
- Subjects :
- Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal adverse effects
Antineoplastic Agents, Immunological adverse effects
C-Reactive Protein metabolism
Clinical Decision-Making
Disease-Free Survival
Female
France
Humans
L-Lactate Dehydrogenase blood
Leukocyte Count
Lymphocytes
Male
Melanoma blood
Melanoma mortality
Melanoma pathology
Middle Aged
Monocytes
Multivariate Analysis
Neutrophils
Nivolumab
Patient Selection
Pilot Projects
Predictive Value of Tests
Proportional Hazards Models
Retrospective Studies
Skin Neoplasms blood
Skin Neoplasms mortality
Skin Neoplasms pathology
Time Factors
Treatment Outcome
Antibodies, Monoclonal therapeutic use
Antineoplastic Agents, Immunological therapeutic use
Biomarkers, Pharmacological blood
Biomarkers, Tumor blood
Leukocytes
Melanoma drug therapy
Skin Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1651-2057
- Volume :
- 98
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Acta dermato-venereologica
- Publication Type :
- Academic Journal
- Accession number :
- 29327065
- Full Text :
- https://doi.org/10.2340/00015555-2872